Artizan Biosciences is creating a new class of transformative precision therapeutics that target and block the root causes of diverse, serious diseases triggered by intestinal inflammation.
Broad Approach
Using multi-modality approaches, Artizan corrects intestinal dysbiosis by neutralizing the core triggers of the inflammatory process.
Discovery Platform
Artizan’s proprietary drug discovery platform identifies and characterizes microbial drivers of disease within precise patient subsets in certain cancers and gastrointestinal, metabolic, autoimmune, and neurodegenerative diseases.
News
-
March 29, 2022
Artizan Biosciences Announces Issuance of New U.S. Patent to Cover Proprietary Discovery Platform
Artizan Biosciences, Inc. (“Artizan”), a biotechnology company creating a new class of transformative precision therapeutics that target and block the root causes of diverse, serious diseases triggered by intestinal inflammation, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,299,790 that broadens the use of the company’s proprietary IgA-SEQ™ discovery platform. (more…)
-
January 18, 2022
Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic Development Program
Artizan Biosciences, Inc., a precision medicine biotechnology company, today announced the selection of its lead product candidate, ARZC-001, for the treatment of inflammatory bowel disease (“IBD”). (more…)
Artizan’s world-class biobanking program collects proprietary samples and clinical data from patients and healthy controls. These samples enable critical research into disease mechanisms and aid the development of potential treatments.